Celgene
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Multiple Sclerosis, Relapsing-Remitting
Ozanimod
Fingolimod
Placebo
PHASE3
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 194 participants |
Masking : | QUADRUPLE |
Primary Purpose : | TREATMENT |
Official Title : | A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis |
Actual Study Start Date : | 2025-01-28 |
Estimated Primary Completion Date : | 2031-04-11 |
Estimated Study Completion Date : | 2036-07-13 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 10 Years to 17 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Local Institution - 0130
Sacramento, California, United States, 95817
Not yet recruiting
UCSF Benioff Children's Hospital San Francisco
San Francisco, California, United States, 94158
Not yet recruiting
Axiom Clinical Research of Florida
Tampa, florida, United States, 33609
Not yet recruiting
University of South Florida
Tampa, florida, United States, 33612
Not yet recruiting
Washington University
St. Louis, Missouri, United States, 63110
Not yet recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Not yet recruiting
Local Institution - 0078
Mexico City, DIF, Mexico, 04530
Not yet recruiting
Local Institution - 0088
Bucharest, Bucharest, Romania, 022102
Not yet recruiting
Local Institution - 0109
Samsun, Turkey, 55270